Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at StockNews.com
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Check Out Our Latest […]
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Check Out Our Latest […]
